Lantern Pharma Inc. LTRN Archives

ThursdayOct 01, 2026 9:00 am

QualityStocksNewsBreaks – Lantern Pharma (NASDAQ: LTRN) Closes $4 Million Registered Direct Offering

Lantern Pharma (NASDAQ: LTRN), a clinical-stage, AI-native biopharma company using artificial intelligence and genomic data to develop precision oncology therapies, announced the closing of its previously announced registered direct offering of 3,669,725 shares of common stock, or pre-funded warrants in lieu thereof, at $1.09 per share. The offering generated approximately $4 million in gross proceeds before fees and expenses. In a concurrent private placement, Lantern issued unregistered warrants to purchase up to 3,669,725 shares at an exercise price of $1.09 per share, potentially providing an additional approximately $4 million in gross proceeds if fully exercised for cash. The company intends…

TuesdaySep 29, 2026 9:30 am

QualityStocksNewsBreaks – Lantern Pharma (NASDAQ: LTRN) Announces $4 Million Registered Direct Offering

Lantern Pharma (NASDAQ: LTRN) announced a definitive agreement for the purchase and sale of 3,669,725 shares of common stock, or pre-funded warrants in lieu thereof, at $1.09 per share in a registered direct offering expected to generate approximately $4 million in gross proceeds. In a concurrent private placement, the company will issue unregistered warrants to purchase up to 3,669,725 additional shares at an exercise price of $1.09 per share, potentially generating approximately $4 million in additional gross proceeds if fully exercised for cash. The offering is expected to close on or about Sept. 30, 2026, subject to customary closing conditions,…

WednesdaySep 23, 2026 9:10 am

QualityStocksNewsBreaks – Lantern Pharma (NASDAQ: LTRN) to Present Open-Medicine AI Growth Plan, Live Platform Demo in Webinar

Lantern Pharma (NASDAQ: LTRN) will present the growth plan for Open-Medicine AI (“OMAI”), its wholly owned subsidiary developing a multi-agentic AI platform for drug development, during a live webinar today at 12:30 p.m. Eastern. CEO Panna Sharma will lead the 45-minute session, which will cover OMAI market opportunity, customer feedback, platform capabilities, development roadmap, economics, benchmarks, potential partnerships and contribution to shareholder value. OMAI core capabilities and initial platform were developed within Lantern clinical programs and areas of focus. Launched as withZeta.ai in April 2026 with an initial focus on rare cancers, the platform is expanding into additional diseases, therapy…

TuesdaySep 22, 2026 9:30 am

QualityStocksNewsBreaks – Lantern Pharma (NASDAQ: LTRN) Receives USPTO Notice of Allowance for LP-284 Blood Cancer Treatment Patent

Lantern Pharma (NASDAQ: LTRN), an AI-driven precision oncology company, announced that the United States Patent and Trademark Office ("USPTO") issued a Notice of Allowance for U.S. Patent Application No. 18/500,032, covering methods of using LP-284 to treat mantle cell lymphoma ("MCL"), double-hit lymphoma ("DHL") and other blood cancers. The allowed claims include LP-284 as a monotherapy and in combination with several classes of anti-cancer agents. Once issued, the patent is expected to extend LP-284 intellectual property protection into 2042, adding method-of-use protection to Lantern existing composition-of-matter patent estate. Lantern Pharma (NASDAQ: LTRN) is evaluating LP-284 in an ongoing Phase 1a…

WednesdayDec 03, 2025 11:45 am

QualityStocksNewsBreaks – Lantern Pharma (NASDAQ: LTRN) Details Encouraging LP-184 Phase 1a Results Showing Durable Disease Control in Advanced Solid Tumors

Lantern Pharma (NASDAQ: LTRN), a clinical-stage biotechnology company using artificial intelligence and genomics to transform oncology drug development, reported additional details and clinical insights from its completed Phase 1a dose-escalation study of LP-184 along with highlights from a recent webinar. The study in 63 heavily pre-treated patients with advanced solid tumors met all primary endpoints for safety and tolerability and established a clear recommended Phase 2 dose. Encouraging signals of durable disease control were observed, particularly in tumors with DNA damage repair pathway deficiencies. Building on these results, Lantern is advancing multiple biomarker-guided Phase 1b/2 trials across triple-negative breast cancer,…

ThursdayNov 13, 2025 10:30 am

QualityStocksNewsBreaks – Lantern Pharma (NASDAQ: LTRN) Reports Q3 2025 Results and Highlights AI-Driven Clinical Progress

Lantern Pharma (NASDAQ: LTRN) reported third-quarter 2025 results and advanced multiple AI-driven oncology programs, highlighted by completion of enrollment and achievement of all primary endpoints in the LP-184 Phase 1a trial, which showed a 48% clinical benefit rate at or above the therapeutic dose threshold along with a favorable safety profile and strong biomarker correlations. The company also outlined plans for Phase 1b/2 studies in TNBC, NSCLC with STK11/KEAP1 co-mutations, and bladder cancer, supported by pharmacokinetic data establishing a recommended Phase 2 dose of 0.39 mg/kg. Lantern noted catalyst-rich progress across its pipeline, including regulatory clarity for its pediatric CNS…

ThursdayOct 30, 2025 9:00 am

QualityStocksNewsBreaks – Lantern Pharma (NASDAQ: LTRN) to Present AI Drug Discovery Platforms at Inaugural AI4BM Symposium

Lantern Pharma (NASDAQ: LTRN) will present its commercially deployed AI research platforms, predictBBB.ai and LBx-AI, at the inaugural AI for Biology and Medicine symposium hosted by the University of North Texas. The company will showcase how machine learning is accelerating drug development and precision oncology, including 94.1% accuracy in predicting blood-brain barrier permeability and 86% accuracy in treatment response prediction for non-small cell lung cancer. CEO Panna Sharma said the presentations highlight Lantern’s mission to democratize advanced computational tools and reshape how pharmaceutical companies approach discovery, biomarker development, and CNS-targeted therapeutics. To view the full press release, visit https://ibn.fm/hgxZQ About…

TuesdayOct 28, 2025 11:00 am

QualityStocksNewsBreaks – Lantern Pharma (NASDAQ: LTRN) Reports Complete Metabolic Response in Phase 1 LP-284 Trial at LL&M Congress

Lantern Pharma (NASDAQ: LTRN), a clinical-stage biopharmaceutical company using its RADR(R) AI platform to transform oncology drug discovery and development, presented clinical data from its ongoing Phase 1 trial of LP-284 at the 25th Annual Lymphoma, Leukemia & Myeloma Congress in New York City, showing a confirmed complete metabolic response in a 41-year-old patient with aggressive Grade 3 non-germinal center B-cell diffuse large B-cell lymphoma after failure of four prior regimens, including CAR-T and bispecific antibody therapies. The response, achieved after two 28-day cycles of LP-284, supports the drug’s synthetic lethal mechanism and potential to fill a critical post-immunotherapy treatment…

FridayOct 24, 2025 9:30 am

QualityStocksNewsBreaks – Lantern Pharma (NASDAQ: LTRN) to Present at ThinkEquity Conference on Oct. 30

Lantern Pharma (NASDAQ: LTRN), an artificial intelligence (AI) company focused on developing cancer therapies and transforming the cost, pace, and timeline of oncology drug discovery, announced that its management team will present at the ThinkEquity Conference on Thursday, Oct. 30, 2025, at 11:30 a.m. ET at the Mandarin Oriental in New York. To view the full press release, visit https://ibn.fm/kCLdf About Lantern Pharma Lantern Pharma (NASDAQ: LTRN) is an AI company transforming the cost, pace, and timeline of oncology drug discovery and development. Our proprietary AI and machine learning (ML) platform, RADR(R), leverages over 200 billion oncology-focused data points and…

TuesdayOct 14, 2025 3:41 pm

QualityStocksNewsBreaks – RADR(R) Platform Powers Lantern Pharma Inc.’s (NASDAQ: LTRN) Push Into Rare Pediatric Brain Cancer Treatment

Lantern Pharma (NASDAQ: LTRN) is developing a number of clinical trials, using its proprietary drug candidates and computational biology and machine learning platform, to target conditions with unmet medical needs. The company was featured in a recent article that discussed its preparation for the launch of a trial targeting a rare pediatric disease, planned for Q1 2026. This comes “in the wake of its optimistic meeting with the U.S. Food and Drug Administration (‘FDA’) to receive critical guidance on the company’s trial design and the FDA’s regulatory pathway… Lantern Pharma is developing its clinical trial with the hope of demonstrating the…

Site Search

Company Search

Tag: Lantern Pharma Inc. LTRN